Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
AC Immune’s stock fell 9 percent on the news that the company’s Phase II Lauriet study of the investigational anti-Tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer’s disease (AD) did not meet all endpoints.
Cortexyme Inc. said on Oct. 26 the company’s experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer’s disease in a study.
Cassava Sciences announced top-line results Sept. 22 from a 12-month interim analysis of the company’s Alzheimer’s drug candidate simufilam.
One of the eagerly anticipated presentations at the 2021 Alzheimer’s Association International Conference in Denver and virtually is Biogen and the company’s partner Eisai on their controversial drug Aduhelm (aducanumab). Biogen is also presenting new data on a different Alzheimer’s drug with another partner, Ionis Pharmaceuticals.
BioSpace takes a look at some of the stories from the first day of the Alzheimer’s Association International Conference 2021 (AAIC).
An investigational Alzheimer’s disease (AD) drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.
The Canadian Down Syndrome Society (CDSS) is partnering with Dr. Dan Gordon and his research team from Anglia Ruskin University and with Dr. Michael Merzenich and his team from BrainHQ to launch a research study and awareness campaign to examine this potential link between physical fitness and mental fitness for people with Down syndrome.
U.S. health experts this week will decide whether to recommend approval for Biogen Inc.’s experimental Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if the antibody aducanumab works.
A new study suggests that some patients could see a decline in cognition that is equivalent to the brain aging approximately 10 years.